{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:46:31Z","timestamp":1792014391975,"version":"4.4.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Progressive supranuclear palsy (PSP) is a fatal tauopathy presenting an unmet medical need. Davunetide, targeting tauopathy, has been previously tested in PSP, which, when separated by sex, implied efficacy in women. Here, efficacy was evaluated using longitudinal data (52 weeks) and applying for the first time, the US Food and Drug Administration (FDA) -recommended 10-item PSP Rating Scale (PSPRS-10) compared to the 28-item PSPRS (primary endpoint). Time-, sex-, and treatment-related effects were analyzed using linear mixed-effects models including the FDA-recommended Mixed Models for Repeated Measures (MMRM). Cognitive evaluations used the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Clinical analyses at the individual level accentuated the impact of the 10 PSPRS chosen items and revealed a significant treatment effect favoring women when accounting for time, sex, and treatment interactions (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0005). Motor measurements were highlighted. RBANS analyses demonstrated women\u2019s significant improvements in total raw score, letter\u2013number sequencing, and language scores. Correlating cerebrospinal fluid (CSF) phosphorylated Tau\/Tau with functional outcomes revealed significance with p-Tau\/Tau ratio and grasping\/imitative\/utilizing behavior (assessing involuntary actions in PSPRS-28). This correlation was opposite in direction between females (r\u2009=\u20090.77;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.006) and males (r\u2009=\u2009-0.62;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.075), with sex difference showing a\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0002 value. Similar results were obtained for language. Predicting the final PSPRS score (week 52), addressing all clinical measures, a clear woman-treatment-specific pattern in outcome importance was discovered, highlighting significance for the primary endpoint Schwab and England Activity of Daily Living (SEADL) scale, and stressing the necessity for sex-specific medicine with davunetide as a lead compound.\n                  <\/jats:p>","DOI":"10.1038\/s41380-026-03709-x","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:30:04Z","timestamp":1783060204000},"page":"6401-6412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9376-4955","authenticated-orcid":false,"given":"Guy","family":"Shapira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liri S.","family":"Guz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Shomron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9796-2430","authenticated-orcid":false,"given":"Illana","family":"Gozes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"3709_CR1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jamaneurol.2025.0013","volume":"82","author":"GT Coughlan","year":"2025","unstructured":"Coughlan GT, Klinger HM, Boyle R, Betthauser TJ, Binette AP, Christenson L, et al. Sex differences in longitudinal tau-PET in preclinical alzheimer disease: a meta-analysis. JAMA Neurol. 2025;82:364\u201375.","journal-title":"JAMA Neurol"},{"key":"3709_CR2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.neurobiolaging.2009.04.006","volume":"32","author":"M Yue","year":"2011","unstructured":"Yue M, Hanna A, Wilson J, Roder H, Janus C. Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiol Aging. 2011;32:590\u2013603.","journal-title":"Neurobiol Aging"},{"key":"3709_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/mp.2015.208","volume":"21","author":"N Amram","year":"2016","unstructured":"Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, et al. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Mol Psychiatry. 2016;21:1467\u201376.","journal-title":"Mol Psychiatry"},{"key":"3709_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13024-015-0011-1","volume":"10","author":"L Song","year":"2015","unstructured":"Song L, Lu SX, Ouyang X, Melchor J, Lee J, Terracina G, et al. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. Mol Neurodegener. 2015;10:14.","journal-title":"Mol Neurodegener"},{"key":"3709_CR5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biopsych.2021.09.018","volume":"92","author":"G Karmon","year":"2022","unstructured":"Karmon G, Sragovich S, Hacohen-Kleiman G, Ben-Horin-Hazak I, Kasparek P, Schuster B, et al. Novel ADNP syndrome mice reveal dramatic sex-specific peripheral gene expression with brain synaptic and tau pathologies. Biol Psychiatry. 2022;92:81\u201395.","journal-title":"Biol Psychiatry"},{"key":"3709_CR6","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1038\/s41380-024-02879-w","volume":"30","author":"G Shapira","year":"2025","unstructured":"Shapira G, Karmon G, Hacohen-Kleiman G, Ganaiem M, Shazman S, Theotokis P, et al. ADNP is essential for sex-dependent hippocampal neurogenesis, through male unfolded protein response and female mitochondrial gene regulation. Mol Psychiatry. 2025;30:2696\u2013706.","journal-title":"Mol Psychiatry"},{"key":"3709_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00904-4","volume":"10","author":"I Grigg","year":"2020","unstructured":"Grigg I, Ivashko-Pachima Y, Hait TA, Korenkova V, Touloumi O, Lagoudaki R, et al. Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Transl Psychiatry. 2020;10:228.","journal-title":"Transl Psychiatry"},{"key":"3709_CR8","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41380-019-0563-5","volume":"26","author":"Y Ivashko-Pachima","year":"2021","unstructured":"Ivashko-Pachima Y, Hadar A, Grigg I, Korenkova V, Kapitansky O, Karmon G, et al. Discovery of autism\/intellectual disability somatic mutations in Alzheimer\u2019s brains: mutated ADNP cytoskeletal impairments and repair as a case study. Mol Psychiatry. 2021;26:1619\u201333.","journal-title":"Mol Psychiatry"},{"key":"3709_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12031-008-9105-3","volume":"36","author":"I Gozes","year":"2008","unstructured":"Gozes I. VIP, from gene to behavior and back: summarizing my 25 years of research. J Mol Neurosci. 2008;36:115\u201324.","journal-title":"J Mol Neurosci"},{"key":"3709_CR10","doi-asserted-by":"crossref","first-page":"115573","DOI":"10.1016\/j.addr.2025.115573","volume":"220","author":"A Galushkin","year":"2025","unstructured":"Galushkin A, Gozes I. Intranasal NAP (Davunetide): neuroprotection and circadian rhythmicity. Adv Drug Deliv Rev. 2025;220:115573.","journal-title":"Adv Drug Deliv Rev"},{"key":"3709_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1073\/pnas.93.1.427","volume":"93","author":"I Gozes","year":"1996","unstructured":"Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA. 1996;93:427\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3709_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02918891","volume":"1","author":"I Gozes","year":"1989","unstructured":"Gozes I, Werner H, Fawzi M, Abdelatty A, Shani Y, Fridkin M, et al. Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. J Mol Neurosci. 1989;1:55\u201361.","journal-title":"J Mol Neurosci"},{"key":"3709_CR13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1471-4159.1999.0721283.x","volume":"72","author":"M Bassan","year":"1999","unstructured":"Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem. 1999;72:1283\u201393.","journal-title":"J Neurochem"},{"key":"3709_CR14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0165-3806(03)00162-7","volume":"144","author":"A Pinhasov","year":"2003","unstructured":"Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res. 2003;144:83\u201390.","journal-title":"Brain Res Dev Brain Res"},{"key":"3709_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03675-y","volume":"15","author":"I Gozes","year":"2025","unstructured":"Gozes I, Blatt J, Guz LS. Systemic davunetide provides sex-specific neuroprotection during coronary artery bypass grafting (CABG). Transl Psychiatry. 2025;15:454.","journal-title":"Transl Psychiatry"},{"key":"3709_CR16","doi-asserted-by":"publisher","unstructured":"Sragovich S, Merenlender-Wagner A, Gozes I ADNP Plays a key role in autophagy: from autism to schizophrenia and alzheimer\u2019s disease. Bioessays 2017;39 https:\/\/doi.org\/10.1002\/bies.201700054.","DOI":"10.1002\/bies.201700054"},{"key":"3709_CR17","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/ejn.15920","volume":"58","author":"I Gozes","year":"2023","unstructured":"Gozes I, Shazman S. A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome. Eur J Neurosci. 2023;58:2641\u201352.","journal-title":"Eur J Neurosci"},{"key":"3709_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/mp.2016.255","volume":"22","author":"Y Ivashko-Pachima","year":"2017","unstructured":"Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I. ADNP\/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol Psychiatry. 2017;22:1335\u201344.","journal-title":"Mol Psychiatry"},{"key":"3709_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/bs.pmbts.2020.07.008","volume":"177","author":"Y Ivashko-Pachima","year":"2021","unstructured":"Ivashko-Pachima Y, Gozes I. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. Prog Mol Biol Transl Sci. 2021;177:65\u201390.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"3709_CR20","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1172\/JCI98199","volume":"128","author":"G Hacohen-Kleiman","year":"2018","unstructured":"Hacohen-Kleiman G, Sragovich S, Karmon G, Gao AYL, Grigg I, Pasmanik-Chor M, et al. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. J Clin Invest. 2018;128:4956\u201369.","journal-title":"J Clin Invest"},{"key":"3709_CR21","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1038\/s41380-022-01603-w","volume":"27","author":"Y Ivashko-Pachima","year":"2022","unstructured":"Ivashko-Pachima Y, Ganaiem M, Ben-Horin-Hazak I, Lobyntseva A, Bellaiche N, Fischer I, et al. SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism. Mol Psychiatry. 2022;27:3316\u201327.","journal-title":"Mol Psychiatry"},{"key":"3709_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03118-0","volume":"14","author":"I Gozes","year":"2024","unstructured":"Gozes I, Blatt J, Lobyntseva A. Davunetide sex-dependently boosts memory in prodromal Alzheimer\u2019s disease. Transl Psychiatry. 2024;14:412.","journal-title":"Transl Psychiatry"},{"key":"3709_CR23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.107.129551","volume":"323","author":"I Vulih-Shultzman","year":"2007","unstructured":"Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007;323:438\u201349.","journal-title":"J Pharmacol Exp Ther"},{"key":"3709_CR24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2022.03.011","volume":"92","author":"H Amal","year":"2022","unstructured":"Amal H. Sex and the brain: novel ADNP syndrome mice are protected by NAP. Biol Psychiatry. 2022;92:8\u20139.","journal-title":"Biol Psychiatry"},{"key":"3709_CR25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neulet.2004.09.077","volume":"373","author":"S Furman","year":"2005","unstructured":"Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, et al. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett. 2005;373:73\u201378.","journal-title":"Neurosci Lett"},{"key":"3709_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02618-9","volume":"13","author":"I Gozes","year":"2023","unstructured":"Gozes I, Shapira G, Lobyntseva A, Shomron N. Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women. Transl Psychiatry. 2023;13:319.","journal-title":"Transl Psychiatry"},{"key":"3709_CR27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/mds.27336","volume":"33","author":"HK Park","year":"2018","unstructured":"Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, et al. Lifetime exposure to estrogen and progressive supranuclear palsy: environmental and genetic PSP study. Mov Disord. 2018;33:468\u201372.","journal-title":"Mov Disord"},{"key":"3709_CR28","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70485","volume":"21","author":"I Garcia-Cordero","year":"2025","unstructured":"Garcia-Cordero I, Vargas-Gonzalez JC, Hadian M, Bayram E, Rodriguez-Porcel F, Couto B, et al. Language impairment is associated with faster progression in progressive supranuclear palsy-richardson syndrome. Alzheimers Dement. 2025;21:e70485.","journal-title":"Alzheimers Dement"},{"key":"3709_CR29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00702-025-03004-z","volume":"133","author":"Y Abida","year":"2026","unstructured":"Abida Y, Sghaier I, Souissi A, Gharbi A, Nasri A, Belkehia O, et al. Motor and non-motor features in progressive supranuclear palsy: the impact of microtubule associated protein tau haplotypes among a Tunisian cohort. J Neural Transm (Vienna). 2026;133:423\u201332.","journal-title":"J Neural Transm (Vienna)"},{"key":"3709_CR30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 2014;13:676\u201385.","journal-title":"Lancet Neurol"},{"key":"3709_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76668-4","volume":"14","author":"E Yousefi","year":"2024","unstructured":"Yousefi E, Gewily M, Konig F, Hoglinger G, Hopfner F, Karlsson MO, et al. Efficiency of multivariate tests in trials in progressive supranuclear palsy. Sci Rep. 2024;14:25581.","journal-title":"Sci Rep"},{"key":"3709_CR32","doi-asserted-by":"crossref","first-page":"fcaf022","DOI":"10.1093\/braincomms\/fcaf022","volume":"7","author":"C Marotta","year":"2025","unstructured":"Marotta C, Sinclair B, O\u2019Brien TJ, Vivash L. Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials. Brain Commun. 2025;7:fcaf022.","journal-title":"Brain Commun"},{"key":"3709_CR33","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/mds.30001","volume":"39","author":"M Gewily","year":"2024","unstructured":"Gewily M, Plan EL, Yousefi E, Konig F, Posch M, Hopfner F, et al. Quantitative comparisons of progressive supranuclear palsy rating scale versions using item response theory. Mov Disord. 2024;39:2181\u20139.","journal-title":"Mov Disord"},{"key":"3709_CR34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310\u20139.","journal-title":"J Clin Exp Neuropsychol"},{"key":"3709_CR35","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018;90:e273\u2013e281.","journal-title":"Neurology"},{"key":"3709_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.04.014","volume":"28","author":"J Bang","year":"2016","unstructured":"Bang J, Lobach IV, Lang AE, Grossman M, Knopman DS, Miller BL, et al. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016;28:41\u201348.","journal-title":"Parkinsonism Relat Disord"},{"key":"3709_CR37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.32614\/RJ-2020-013","volume":"12","author":"BM Greenwell","year":"2020","unstructured":"Greenwell BM, Boehmke BC. Variable importance plots\u2014an introduction to the vip package. The R Journal. 2020;12:343\u201366.","journal-title":"The R Journal"},{"key":"3709_CR38","first-page":"Article 9","volume":"4","author":"K Lu","year":"2008","unstructured":"Lu K, Luo X, Chen PY. Sample size estimation for repeated measures analysis in randomized clinical trials with missing data. Int J Biostat. 2008;4:Article 9.","journal-title":"Int J Biostat"},{"key":"3709_CR39","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/mds.26694","volume":"31","author":"S Hewer","year":"2016","unstructured":"Hewer S, Varley S, Boxer AL, Paul E, Williams DR, Investigators AL. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. Mov Disord. 2016;31:1574\u20137.","journal-title":"Mov Disord"},{"key":"3709_CR40","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1007\/s00415-023-11807-x","volume":"270","author":"P Ananthavarathan","year":"2023","unstructured":"Ananthavarathan P, Patel B, Peeros S, Obrocki R, Malek N. Neurological update: non-motor symptoms in atypical parkinsonian syndromes. J Neurol. 2023;270:4558\u201378.","journal-title":"J Neurol"},{"key":"3709_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v064.i08","volume":"64","author":"A Touloumis","year":"2015","unstructured":"Touloumis A. R package multgee: a generalized estimating equations solver for multinomial responses. J Stat Softw. 2015;64:1\u201314.","journal-title":"J Stat Softw"},{"key":"3709_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03168-z","volume":"19","author":"E Nysetvold","year":"2024","unstructured":"Nysetvold E, Lopez LN, Cogell AN, Fryk H, Pace ND, Taylor SS, et al. Progressive supranuclear palsy (PSP) disease progression, management, and healthcare resource utilization: a retrospective observational study in the US and Canada. Orphanet J Rare Dis. 2024;19:215.","journal-title":"Orphanet J Rare Dis"},{"key":"3709_CR43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-3-7091-6641-3_15","volume":"42","author":"J Winikates","year":"1994","unstructured":"Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:189\u2013201.","journal-title":"J Neural Transm Suppl"},{"key":"3709_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53355-y","volume":"14","author":"P Alster","year":"2024","unstructured":"Alster P, Otto-Slusarczyk D, Szlufik S, Duszynska-Was K, Drzewinska A, Wiercinska-Drapalo A, et al. The significance of glial cell line-derived neurotrophic factor analysis in progressive supranuclear palsy. Sci Rep. 2024;14:2805.","journal-title":"Sci Rep"},{"key":"3709_CR45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jad.2022.09.123","volume":"320","author":"L Ding","year":"2023","unstructured":"Ding L, Wu Y, Kong L, Sun J, Qu F, Xin K, et al. Gender differences in plasma glial cell line-derived neurotrophic factor levels of patients with bipolar disorder. J Affect Disord. 2023;320:605\u20139.","journal-title":"J Affect Disord"},{"key":"3709_CR46","first-page":"887","volume":"147","author":"SC Parlar","year":"2026","unstructured":"Parlar SC, Yu E, Kanagasingam S, Zhang M, Liu L, Shahkhali MG, et al. Machine learning and burden analyses highlight novel genes in Parkinson\u2019s. Disease Brain. 2026;147:887\u201399.","journal-title":"Disease Brain"},{"key":"3709_CR47","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1038\/s41380-021-01143-9","volume":"26","author":"A Hadar","year":"2021","unstructured":"Hadar A, Kapitansky O, Ganaiem M, Sragovich S, Lobyntseva A, Giladi E, et al. Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. Mol Psychiatry. 2021;26:6550\u201361.","journal-title":"Mol Psychiatry"},{"key":"3709_CR48","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp.2003.020982","volume":"75","author":"GF Wooten","year":"2004","unstructured":"Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson\u2019s disease than women? J Neurol Neurosurg Psychiatry. 2004;75:637\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3709_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s13760-021-01599-0","volume":"122","author":"RR Mahale","year":"2022","unstructured":"Mahale RR, Krishnan S, Divya KP, Jisha VT, Kishore A. Gender differences in progressive supranuclear palsy. Acta Neurol Belg. 2022;122:357\u201362.","journal-title":"Acta Neurol Belg"},{"key":"3709_CR50","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/mds.30150","volume":"40","author":"H Wang","year":"2025","unstructured":"Wang H, Chang TS, Dombroski BA, Cheng PL, Si YQ, Tucci A, et al. Copy number variation and haplotype analysis of 17q21.31 reveals increased risk associated with progressive supranuclear palsy and gene expression changes in neuronal cells. Mov Disord. 2025;40:950\u201361.","journal-title":"Mov Disord"},{"key":"3709_CR51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-022-00551-x","volume":"17","author":"KR Bowles","year":"2022","unstructured":"Bowles KR, Pugh DA, Liu Y, Patel T, Renton AE, Bandres-Ciga S, et al. 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson\u2019s disease are associated with LRRC37A\/2 expression in astrocytes. Mol Neurodegener. 2022;17:48.","journal-title":"Mol Neurodegener"},{"key":"3709_CR52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-024-00731-x","volume":"19","author":"C Pedicone","year":"2024","unstructured":"Pedicone C, Weitzman SA, Renton AE, Goate AM. Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases. Mol Neurodegener. 2024;19:43.","journal-title":"Mol Neurodegener"},{"key":"3709_CR53","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40120-025-00884-x","volume":"15","author":"KS Moore","year":"2026","unstructured":"Moore KS, Stipho YS, Niemann N, Shill HA, Chan J, Abrego CJ, et al. Dementia in progressive supranuclear palsy: a narrative review. Neurol Ther. 2026;15:479\u201396.","journal-title":"Neurol Ther"},{"key":"3709_CR54","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105454","volume":"112","author":"LA Digma","year":"2023","unstructured":"Digma LA, Litvan I, Del Ser T, Bayram E. Sex differences for cognitive decline in progressive supranuclear palsy. Parkinsonism Relat Disord. 2023;112:105454.","journal-title":"Parkinsonism Relat Disord"},{"key":"3709_CR55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41586-024-08457-y","volume":"638","author":"S Abdulai-Saiku","year":"2025","unstructured":"Abdulai-Saiku S, Gupta S, Wang D, Marino F, Moreno AJ, Huang Y, et al. The maternal X chromosome affects cognition and brain ageing in female mice. Nature. 2025;638:152\u20139.","journal-title":"Nature"},{"key":"3709_CR56","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ads8169","volume":"11","author":"M Gadek","year":"2025","unstructured":"Gadek M, Shaw CK, Abdulai-Saiku S, Saloner R, Marino F, Wang D, et al. Aging activates escape of the silent X chromosome in the female mouse hippocampus. Sci Adv. 2025;11:eads8169.","journal-title":"Sci Adv"},{"key":"3709_CR57","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jamaneurol.2024.2843","volume":"81","author":"ME Belloy","year":"2024","unstructured":"Belloy ME, Le Guen Y, Stewart I, Williams K, Herz J, Sherva R, et al. Role of the X chromosome in alzheimer disease genetics. JAMA Neurol. 2024;81:1032\u201342.","journal-title":"JAMA Neurol"},{"key":"3709_CR58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajhg.2024.11.008","volume":"112","author":"M Mendes","year":"2025","unstructured":"Mendes M, Chen DZ, Engchuan W, Leal TP, Thiruvahindrapuram B, Trost B, et al. Chromosome X-wide common variant association study in autism spectrum disorder. Am J Hum Genet. 2025;112:135\u201353.","journal-title":"Am J Hum Genet"},{"key":"3709_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14283\/jpad.2018.34","volume":"5","author":"O Scheyer","year":"2018","unstructured":"Scheyer O, Rahman A, Hristov H, Berkowitz C, Isaacson RS, Diaz Brinton R, et al. Female sex and alzheimer\u2019s risk: the menopause connection. J Prev Alzheimers Dis. 2018;5:225\u201330.","journal-title":"J Prev Alzheimers Dis"},{"key":"3709_CR60","doi-asserted-by":"crossref","first-page":"e0324652","DOI":"10.1371\/journal.pone.0324652","volume":"20","author":"Z Jin","year":"2025","unstructured":"Jin Z, Liu N, Wei H. Atherosclerosis is associated with amyloid and tau pathology via blood-brain barrier dysfunction in the hippocampus of aged human brains. PLoS ONE. 2025;20:e0324652.","journal-title":"PLoS ONE"},{"key":"3709_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38374-z","volume":"14","author":"T Bourquard","year":"2023","unstructured":"Bourquard T, Lee K, Al-Ramahi I, Pham M, Shapiro D, Lagisetty Y, et al. Functional variants identify sex-specific genes and pathways in Alzheimer\u2019s Disease. Nat Commun. 2023;14:2765.","journal-title":"Nat Commun"},{"key":"3709_CR62","doi-asserted-by":"crossref","unstructured":"Bayram E, Carter DJ, Aslam S, Forbes E, Holden SK. Sex differences for clinical presentations and co-pathologies in four-repeat tauopathies. Biol Sex Differ. 2026.","DOI":"10.1186\/s13293-026-00899-5"},{"key":"3709_CR63","doi-asserted-by":"crossref","first-page":"e0253079","DOI":"10.1371\/journal.pone.0253079","volume":"16","author":"Y Takamatsu","year":"2021","unstructured":"Takamatsu Y, Aiba I. Skeletal muscle loss and body composition in progressive supranuclear palsy: A retrospective cross-sectional study. PLoS ONE. 2021;16:e0253079.","journal-title":"PLoS ONE"},{"key":"3709_CR64","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1177\/1877718X251343094","volume":"15","author":"L Ye","year":"2025","unstructured":"Ye L, Greten S, Wilkens I, Wegner F, Krey L, Hollerhage M, et al. Tackling gender in progressive supranuclear palsy: Male patients present more apathy. J Parkinsons Dis. 2025;15:1024\u20138.","journal-title":"J Parkinsons Dis"},{"key":"3709_CR65","doi-asserted-by":"crossref","first-page":"1334862","DOI":"10.3389\/fnmol.2024.1334862","volume":"17","author":"JM Achiro","year":"2024","unstructured":"Achiro JM, Tao Y, Gao F, Lin CH, Watanabe M, Neumann S, et al. Aging differentially alters the transcriptome and landscape of chromatin accessibility in the male and female mouse hippocampus. Front Mol Neurosci. 2024;17:1334862.","journal-title":"Front Mol Neurosci"},{"key":"3709_CR66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm5029","volume":"8","author":"K Tsujikawa","year":"2022","unstructured":"Tsujikawa K, Hamanaka K, Riku Y, Hattori Y, Hara N, Iguchi Y, et al. Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Sci Adv. 2022;8:eabm5029.","journal-title":"Sci Adv"},{"key":"3709_CR67","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1073\/pnas.0736237100","volume":"100","author":"CJ Loy","year":"2003","unstructured":"Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA. 2003;100:4562\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3709_CR68","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/path.3969","volume":"226","author":"DA Nijholt","year":"2012","unstructured":"Nijholt DA, van Haastert ES, Rozemuller AJ, Scheper W, Hoozemans JJ. The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J Pathol. 2012;226:693\u2013702.","journal-title":"J Pathol"},{"key":"3709_CR69","volume":"234","author":"Y Ji","year":"2025","unstructured":"Ji Y, Jiang Q, Chen B, Chen X, Li A, Shen D, et al. Endoplasmic reticulum stress and unfolded protein response: Roles in skeletal muscle atrophy. Biochem Pharmacol. 2025;234:116799.","journal-title":"Biochem Pharmacol"},{"key":"3709_CR70","doi-asserted-by":"crossref","first-page":"e87383","DOI":"10.1371\/journal.pone.0087383","volume":"9","author":"Y Schirer","year":"2014","unstructured":"Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of tau mutation. PLoS ONE. 2014;9:e87383.","journal-title":"PLoS ONE"},{"key":"3709_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.138","volume":"5","author":"A Malishkevich","year":"2015","unstructured":"Malishkevich A, Amram N, Hacohen-Kleiman G, Magen I, Giladi E, Gozes I. Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer\u2019s pathologies. Transl Psychiatry. 2015;5:e501.","journal-title":"Transl Psychiatry"},{"key":"3709_CR72","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3390\/cells9102320","volume":"9","author":"O Kapitansky","year":"2020","unstructured":"Kapitansky O, Karmon G, Sragovich S, Hadar A, Shahoha M, Jaljuli I, et al. Single cell ADNP predictive of human muscle disorders: mouse knockdown results in muscle wasting. Cells. 2020;9:2320.","journal-title":"Cells"},{"key":"3709_CR73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cortex.2020.12.019","volume":"137","author":"DT Smith","year":"2021","unstructured":"Smith DT, Casteau S, Archibald N. Spatial attention and spatial short term memory in PSP and Parkinson\u2019s disease. Cortex. 2021;137:49\u201360.","journal-title":"Cortex"},{"key":"3709_CR74","doi-asserted-by":"crossref","first-page":"e34891","DOI":"10.1371\/journal.pone.0034891","volume":"7","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, Muller AK, Sudmeyer M, Ferrea S, Ringelstein M, Cohn E, et al. Optical coherence tomography in parkinsonian syndromes. PLoS ONE. 2012;7:e34891.","journal-title":"PLoS ONE"},{"key":"3709_CR75","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00417-007-0746-7","volume":"246","author":"T Jehle","year":"2008","unstructured":"Jehle T, Dimitriu C, Auer S, Knoth R, Vidal-Sanz M, Gozes I, et al. The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefes Arch Clin Exp Ophthalmol. 2008;246:1255\u201363.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3709_CR76","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1111\/j.1755-3768.2010.02041.x","volume":"89","author":"M Belokopytov","year":"2011","unstructured":"Belokopytov M, Shulman S, Dubinsky G, Gozes I, Belkin M, Rosner M. Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmol. 2011;89:e126\u2013131.","journal-title":"Acta Ophthalmol"},{"key":"3709_CR77","doi-asserted-by":"crossref","first-page":"13654","DOI":"10.3390\/ijms232113654","volume":"23","author":"G Maugeri","year":"2022","unstructured":"Maugeri G, D\u2019Amico AG, Magri B, Musumeci G, D\u2019Agata V. Activity-dependent neuroprotective protein (ADNP): an overview of its role in the eye. Int J Mol Sci. 2022;23:13654.","journal-title":"Int J Mol Sci"},{"key":"3709_CR78","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam T, Boxer AL, Golbe LI, Hoglinger GU, Morris HR, Litvan I, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27:1451\u20137.","journal-title":"Nat Med"},{"key":"3709_CR79","doi-asserted-by":"publisher","unstructured":"Blatt J, Guz LS, Shabat D, Gozes I. Intranasal bioavailability is estrous-cycle regulated: davunetide as a case study. Genomic Psychiatry. 2026;2:112\u201320. https:\/\/doi.org\/10.61373\/gp026r.0039.","DOI":"10.61373\/gp026r.0039"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03709-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:58:08Z","timestamp":1792011488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03709-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":79,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3709"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03709-x","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of davunetide is under patent protection. Professor Illana Gozes serves as Vice President Drug Development, and Dr. Guy Shapira serves as a consultant to ExoNavis Therapeutics Ltd.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Clinical studies were performed under institutional ethical approval with appropriate informed consents. All methods were performed in accordance with the relevant guidelines and regulations (ClinicalTrials.gov ID NCT01110720).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}